Supportive care for patients with early breast cancer

Clinical and Translational Oncology

Volumn 12, Issue 1, 2010, Pages 32-42

  García Estévez, Laura ^a   Tusquets, Ignasi ^b   Álvarez, Isabel ^c   Rodríguez, César ^d   Fernández, Yolanda ^e   Seguí, Miguel Ángel ^f   García Mata, Jesús ^g   Lluch, Ana ^h  

^a Centro Integral Oncologico Clara Campal   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL DE SABADELL   (Spain)

^g Servizo Galego de Saúde   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Adverse events; Anaemia; Breast cancer; Chemotherapy; Emesis; Neutropenia

Indexed keywords

AMFEBUTAMONE; ANTIANEMIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CISPLATIN; COLONY STIMULATING FACTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN ALPHA; ERYTHROPOIETIN RECEPTOR; ESTROGEN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IRON; METHOTREXATE; METOCLOPRAMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PROCHLORPERAZINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALTERNATIVE MEDICINE; ANEMIA; ANTIBIOTIC PROPHYLAXIS; BREAST CANCER; BURNING SENSATION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NEUTROPENIA; CIMICIFUGA RACEMOSA; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; EARLY CANCER; ERYTHROCYTE TRANSFUSION; ESTROGEN THERAPY; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; INFECTION RISK; INSOMNIA; IRON THERAPY; LIBIDO DISORDER; LOW DRUG DOSE; MENOPAUSAL SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PROPHYLAXIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SECONDARY PREVENTION; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; SKIN TINGLING; SYMPTOM; TREMOR; VAGINAL DRYNESS; VASOMOTOR DISORDER;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; PALLIATIVE CARE; PATIENT CARE TEAM;

EID: 76049125896     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0464-1     Document Type: Review

References (115)

1. G. Fan L. Filipczak E. Chow 2007 Symptom clusters in cancer patients: a review of the literature Curr Oncol 14 173 179 1:STN:280:DC%2BD2snhsVGisA%3D%3D 17938700 10.3747/co.2007.145
2. M.K. Soni D. Cella 2002 Quality of life and symptom measures in oncology: an overview Am J Manag Care 8 S560 573 12512980
3. D.M. Parkin F. Bray J. Ferlay, et al. 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 15761078 10.3322/canjclin.55.2.74
4. M. Ellis 2008 Febrile neutropenia Ann N Y Acad Sci 1138 329 350 18837909 10.1196/annals.1414.035
5. G.H. Lyman 2006 Risks and consequences of chemotherapy-induced neutropenia Clin Cornerstone 8 [Suppl5] S12 18 17379159 10.1016/S1098-3597(06) 80054-2
6. P.A. Pizzo 1993 Management of fever in patients with cancer and treatment-induced neutropenia N Engl J Med 328 1323 1332 1:STN:280: DyaK3s3is1SjtA%3D%3D 8469254 10.1056/NEJM199305063281808 (Pubitemid 23131375)
7. J. Crawford D.C. Dale G.H. Lyman 2004 Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management Cancer 100 228 237 14716755 10.1002/cncr.11882 (Pubitemid 38063629)
8. G. von Minckwitz M. Schwenkglenks T. Skacel, et al. 2009 Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: results from an integrated analysis Eur J Cancer 45 608 617 10.1016/j.ejca.2008.11.021 1:CAS:528:DC%2BD1MXitF2gtrs%3D
9. T.J. Smith J. Khatcheressian G.H. Lyman, et al. 2006 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187 3205 1:CAS:528:DC%2BD28XnslKhsLo%3D 16682719 10.1200/JCO.2006.06.4451 (Pubitemid 46638957)
10. N.M. Kuderer D.C. Dale J. Crawford, et al. 2006 Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258 2266 16575919 10.1002/cncr.21847 (Pubitemid 43673249)
11. I. Chirivella B. Bermejo A. Insa, et al. 2008 Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients Breast Cancer Res Treat 114 479 484 18463977 10.1007/s10549-008-0018-1 1:CAS:528:DC%2BD1MXisFSqt7g%3D
12. American Society of Clinical Oncology 1994 Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines J Clin Oncol 12 2471 2508
13. S.F. Wong H.O. Chan 2005 Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy Pharmacotherapy 25 372 378 15843284 10.1592/phco.25.3.372.61608 (Pubitemid 40300324)
14. M.D. Green H. Koelbl J. Baselga, et al. 2003 A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 29 35 1:STN:280:DC%2BD38jisFektQ%3D%3D 12488289 10.1093/annonc/mdg019 (Pubitemid 36150255)
15. G. von Minckwitz S. Kummel A. du Bois, et al. 2008 Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer Ann Oncol 19 292 298 10.1093/annonc/mdm438 (Pubitemid 351201710)
16. M. Martin A. Lluch M.A. Segui, et al. 2006 Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocytecolony stimulating factor to the TAC regimen Ann Oncol 17 1205 1212 1:STN:280:DC%2BD28vkvVOrtw%3D%3D 16766587 10.1093/annonc/mdl135 (Pubitemid 44288210)
17. M.S. Aapro D.A. Cameron R. Pettengell, et al. 2006 EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours Eur J Cancer 42 2433 2453 1:CAS:528:DC%2BD28XhtVagtrbL 16750358 10.1016/j.ejca.2006.05.002 (Pubitemid 44442936)
18. (2004) NCCN makes changes to its guidelines for treating fever and neutropenia. J Support Oncol 2:319, 355
19. H. Ozer J.O. Armitage C.L. Bennett, et al. 2000 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines J Clin Oncol 18 3558 3585 1:STN:280:DC%2BD3M%2Fhsl2gsw%3D%3D 11032599
20. L. Gianni B.F. Cole I. Panzini, et al. 2008 Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group Support Care Cancer 16 67 74 17629752 10.1007/s00520-007-0295-y (Pubitemid 350243763)
21. F. Tas Y. Eralp M. Basaran, et al. 2002 Anemia in oncology practice: relation to diseases and their therapies Am J Clin Oncol 25 371 379 12151968 10.1097/00000421-200208000-00011 (Pubitemid 34864032)
22. E. Pujade-Lauraine P. Gascon 2004 The burden of anaemia in patients with cancer Oncology 67 [Suppl1] 1 4 15489559 10.1159/000080702 (Pubitemid 39370539)
23. S. Mercadante V. Gebbia A. Marrazzo, et al. 2000 Anaemia in cancer: pathophysiology and treatment Cancer Treat Rev 26 303 311 1:STN:280: DC%2BD3cvhtVentg%3D%3D 10913385 10.1053/ctrv.2000.0181 (Pubitemid 30604041)
24. R.K. Portenoy L.M. Itri 1999 Cancer-related fatigue: guidelines for evaluation and management Oncologist 4 1 10 1:STN:280:DyaK1M3mvFKlsg%3D%3D 10337366
25. T.J. Littlewood E. Bajetta J.W. Nortier, et al. 2001 Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2865 2874 1:CAS:528: DC%2BD3MXltVGgs7k%3D 11387359
26. J. Bohlius S. Langensiepen G. Schwarzer, et al. 2005 Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis J Natl Cancer Inst 97 489 498 1:CAS:528: DC%2BD2MXjtFalt7w%3D 15812074
27. B. Leyland-Jones 2003 Breast cancer trial with erythropoietin terminated unexpectedly Lancet Oncol 4 459 460 12901958 10.1016/S1470-2045(03)01163-X (Pubitemid 37009952)
28. M. Henke R. Laszig C. Rube, et al. 2003 Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial Lancet 362 1255 1260 1:CAS:528: DC%2BD3sXot1Cjt7o%3D 14575968 10.1016/S0140-6736(03)14567-9 (Pubitemid 37324251)
29. M.O. Arcasoy K. Amin A.F. Karayal, et al. 2002 Functional significance of erythropoietin receptor expression in breast cancer Lab Invest 82 911 918 1:CAS:528:DC%2BD38Xmt1Wlsbo%3D 12118093
30. M. Henke D. Mattern M. Pepe, et al. 2006 Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24 4708 4713 1:CAS:528:DC%2BD28XhtFynsr3P 17028293 10.1200/JCO.2006.06.2737 (Pubitemid 46630934)
31. F.R. Khuri 2007 Weighing the hazards of erythropoiesis stimulation in patients with cancer N Engl J Med 356 2445 2448 1:CAS:528:DC%2BD2sXms1Sju7c%3D 17568023 10.1056/NEJMp078101
32. E. Selzer V. Wacheck R. Kodym, et al. 2000 Erythropoietin receptor expression in human melanoma cells Melanoma Res 10 421 426 1:CAS:528: DC%2BD3cXosFShtLw%3D 11095402 10.1097/00008390-200010000-00003 (Pubitemid 30836824)
33. H. Ludwig 2004 rHuEPO and treatment outcomes: the preclinical experience Oncologist 9 [Suppl5] 48 54 1:CAS:528:DC%2BD2MXltVWktg%3D%3D 15591422 10.1634/theoncologist.9-90005-48 (Pubitemid 39658345)
34. M.H. Fenner A. Ganser 2008 Erythropoietin in cancer-related anemia Curr Opin Oncol 20 685 689 1:CAS:528:DC%2BD1cXht1SntLfI 18841051 10.1097/CCO. 0b013e3283136971
35. (2008) http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalproducts/ucm110249.htm. Accessed 2 October 2009
36. G.M. Rodgers 2006 Guidelines for the use of erythropoietic growth factors in patients with chemotherapy-induced anemia Oncology (Williston Park) 20 12 15
37. J.D. Rizzo M.R. Somerfield K.L. Hagerty, et al. 2008 Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update J Clin Oncol 26 132 149 1:CAS:528:DC%2BD1cXhsVCrtrw%3D 17954713 10.1200/JCO.2007.14.3396
38. J.D. Rizzo A.E. Lichtin S.H. Woolf, et al. 2002 Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology J Clin Oncol 20 4083 4107 1:CAS:528:DC%2BD38XntF2js7s%3D 12351606 10.1200/JCO.2002.07.177
39. S.J. Van Belle V. Cocquyt 2003 Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy Crit Rev Oncol Hematol 47 1 11 12853095 10.1016/S1040-8428(03)00093-3 (Pubitemid 36802321)
40. L.S. Schwartzberg L.K. Yee F.M. Senecal, et al. 2004 A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer Oncologist 9 696 707 1:CAS:528:DC%2BD2MXhs1yrsA%3D%3D 15561813 10.1634/theoncologist.9-6-696 (Pubitemid 39546409)
41. M. Auerbach H. Ballard J.R. Trout, et al. 2004 Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial J Clin Oncol 22 1301 1307 1:CAS:528:DC%2BD2cXpsVGktbk%3D 15051778 10.1200/JCO.2004.08. 119 (Pubitemid 41079845)
42. D.H. Henry 1998 Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 3 275 278 1:CAS:528: DyaK1cXlvF2hs7Y%3D 10388116
43. M. Cazzola F. Mercuriali C. Brugnara 1997 Use of recombinant human erythropoietin outside the setting of uremia Blood 89 4248 4267 1:CAS:528:DyaK2sXjvFCnsr0%3D 9192747
44. A. Molassiotis M.P. Saunders J. Valle, et al. 2008 A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre Support Care Cancer 16 201 208 1:STN:280:DC%2BD1c%2FkslCjtA%3D%3D 17926070 10.1007/s00520-007-0343-7
45. K. Jordan C. Sippel H.J. Schmoll 2007 Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations Oncologist 12 1143 1150 1:CAS:528:DC%2BD2sXht1Krs7rO 17914084 10.1634/theoncologist.12-9-1143 (Pubitemid 350007026)
46. J. Lachaine C. Laurier A. Langleben, et al. 1999 Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer Crit Rev Oncol Hematol 32 105 112 1:STN:280:DC%2BD3c%2FnvVWgtg%3D%3D 10612010 10.1016/S1040-8428(99)00025-6 (Pubitemid 29528301)
47. R.J. Gralla D. Osoba M.G. Kris, et al. 1999 Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines American Society of Clinical Oncology. J Clin Oncol 17 2971 2994 1:STN:280:DC%2BD3c%2FjtVWjtw%3D%3D
48. T. Guttuso Jr P. Vitticore R.G. Holloway 2005 Responsiveness of life-threatening refractory emesis to gabapentin-scopolamine therapy following posterior fossa surgery. Case report J Neurosurg 102 547 549 15796394 10.3171/jns.2005.102.3.0547
49. J. Herrstedt 2008 Antiemetics: an update and the MASCC guidelines applied in clinical practice Nat Clin Pract Oncol 5 32 43 1:CAS:528: DC%2BD1cXhtFGntA%3D%3D 18097455 10.1038/ncponc1021
50. S.M. Grunberg D. Osoba P.J. Hesketh, et al. 2005 Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity: an update Support Care Cancer 13 80 84 15599601 10.1007/s00520-004-0718-y (Pubitemid 40558162)
51. R.J. Gralla L.M. Itri S.E. Pisko, et al. 1981 Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting N Engl J Med 305 905 909 1:STN:280:DyaL38%2FhtlCrsQ%3D%3D 7024807
52. S.M. Grunberg P.J. Hesketh 1993 Control of chemotherapy-induced emesis N Engl J Med 329 1790 1796 1:STN:280:DyaK2c%2FltVSltg%3D%3D 8232489 10.1056/NEJM199312093292408 (Pubitemid 23355554)
53. H.J. Schmoll M.S. Aapro S. Poli-Bigelli, et al. 2006 Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment Ann Oncol 17 1000 1006 1:STN:280:DC%2BD283nsleguw%3D%3D 16524979 10.1093/annonc/mdl019 (Pubitemid 43778994)
54. R. de Wit J. Herrstedt B. Rapoport, et al. 2004 The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials Eur J Cancer 40 403 410 14746859
55. M.G. Kris P.J. Hesketh M.R. Somerfield, et al. 2006 American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 J Clin Oncol 24 2932 2947 1:CAS:528:DC%2BD28XntV2gs7k%3D 16717289 10.1200/JCO.2006.06. 9591 (Pubitemid 46630595)
56. F. Roila P.J. Hesketh J. Herrstedt 2006 Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference Ann Oncol 17 20 28 1:STN:280: DC%2BD28%2FkvVKmtQ%3D%3D 16314401 10.1093/annonc/mdj936
57. (2004) Effective interventions for CINV: NCCN Antiemesis Clinical Practice Guidelines in Oncology. ONS News 19:17-18
58. R. Vassilopoulou-Sellin 2003 Breast cancer and hormonal replacement therapy Ann N Y Acad Sci 997 341 350 14644841 10.1196/annals.1290.037 (Pubitemid 38491089)
59. D. Cella L.J. Fallowfield 2008 Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy Breast Cancer Res Treat 107 167 180 1:CAS:528: DC%2BD2sXhsVarurvJ 17876703 10.1007/s10549-007-9548-1 (Pubitemid 350265697)
60. V.C. Jordan 2006 Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer Br J Pharmacol 147[Suppl1] S269 276 10.1038/sj.bjp. 0706399 1:CAS:528:DC%2BD28XisVCnsA%3D%3D (Pubitemid 43077285)
61. C.I. Herold K.L. Blackwell 2008 Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease Clin Breast Cancer 8 50 64 1:CAS:528:DC%2BD1cXkt1Oju74%3D 18501059 10.3816/CBC.2008.n.003 (Pubitemid 351346230)
62. A. Howell J.F. Robertson J. Quaresma Albano, et al. 2002 Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 3396 3403 1:CAS:528:DC%2BD38XntVyjsbs%3D 12177099 10.1200/JCO.2002.10. 057 (Pubitemid 34894672)
63. P. Gupta D.W. Sturdee S.L. Palin, et al. 2006 Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life Climacteric 9 49 58 1:STN:280:DC%2BD28%2FjvFWkuw%3D%3D 16428125 10.1080/13697130500487224 (Pubitemid 43155683)
64. L.R. Schover 1994 Sexuality and body image in younger women with breast cancer J Natl Cancer Inst Monogr 16 177 182 7999462
65. L.B. Wenzel D.L. Fairclough M.J. Brady, et al. 1999 Age-related differences in the quality of life of breast carcinoma patients after treatment Cancer 86 1768 1774 1:STN:280:DC%2BD3c%2Fhs1ejtw%3D%3D 10547550 10.1002/(SICI)1097-0142(19991101)86:9<1768::AID-CNCR19>3.0.CO;2-O (Pubitemid 29513046)
66. C.L. Loprinzi S. Abu-Ghazaleh J.A. Sloan, et al. 1997 Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer J Clin Oncol 15 969 973 1:CAS:528:DyaK2sXitFCgs7g%3D 9060535
67. E.A. Gardner J.A. Johnston 1985 Bupropion: an antidepressant without sexual pathophysiological action J Clin Psychopharmacol 5 24 29 1:STN:280:DyaL2M7jtFyqtA%3D%3D 3919069 10.1097/00004714-198502000-00005
68. A.M. Shadiack S.D. Sharma D.C. Earle, et al. 2007 Melanocortins in the treatment of male and female sexual dysfunction Curr Top Med Chem 7 1137 1144 1:CAS:528:DC%2BD2sXhtVKqtrrL 17584134 10.2174/156802607780906681 (Pubitemid 47044744)
69. Le Veque FG, Hendrix S (2004) Oral pilocarpine to treat vaginal xerosis associated with chemotherapy-induced amenorrhea in pre-menopausal women. In: Journal of Clinical Oncology. ASCO Annual Meeting Proceedings, Detroit
70. L.M. Anllo 2000 Sexual life after breast cancer J Sex Marital Ther 26 241 248 1:STN:280:DC%2BD3M%2FltlGrtw%3D%3D 10929572 10.1080/00926230050084632
71. Collaborative Group on Hormonal Factors in Breast Cancer 1997 Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer Lancet 350 1047 1059 10.1016/S0140-6736(97)08233-0 (Pubitemid 27437855)
72. J.E. Dew B.G. Wren J.A. Eden 2003 A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer Climacteric 6 45 52 1:STN:280:DC%2BD3s3gs1Srtw%3D%3D 12725664
73. D.L. Barton D.B. Wender J.A. Sloan, et al. 2007 Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3 J Natl Cancer Inst 99 672 679 1:CAS:528:DC%2BD2sXmsFarsrs%3D 17470735 10.1093/jnci/djk149 (Pubitemid 47073529)
74. C.H. Mom C. Buijs P.H. Willemse, et al. 2006 Hot flushes in breast cancer patients Crit Rev Oncol Hematol 57 63 77 16343926
75. V. Stearns L. Ullmer J.F. Lopez, et al. 2002 Hot flushes Lancet 360 1851 1861 1:CAS:528:DC%2BD38Xpt12mtro%3D 12480376 10.1016/S0140-6736(02)11774-0 (Pubitemid 35449427)
76. F. Kronenberg 1990 Hot flashes: epidemiology and physiology Ann N Y Acad Sci 592 52 86 1:STN:280:DyaK3czivVKgtQ%3D%3D 2197954 10.1111/j.1749-6632.1990. tb30316.x (Pubitemid 20273207)
77. S. Dalal D.S. Zhukovsky 2006 Pathophysiology and management of hot flashes J Support Oncol 4 315 320 16892692
78. D.W. Stevenson D.J. Delprato 1983 Multiple component self-control program for menopausal hot flashes J Behav Ther Exp Psychiatry 14 137 140 1:STN:280:DyaL2c%2FgvVGgtg%3D%3D 6352742 10.1016/0005-7916(83)90031-9
79. D.L. Barton C.L. Loprinzi S.K. Quella, et al. 1998 Prospective evaluation of vitamin E for hot flashes in breast cancer survivors J Clin Oncol 16 495 500 1:CAS:528:DyaK1cXhtFShtL8%3D 9469333
80. R.M. Goldberg C.L. Loprinzi J.R. O'Fallon, et al. 1994 Transdermal clonidine for ameliorating tamoxifen-induced hot flashes J Clin Oncol 12 155 158 1:STN:280:DyaK2c%2Fps1SmsA%3D%3D 8270972
81. C.L. Loprinzi J.W. Kugler J.A. Sloan, et al. 2000 Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial Lancet 356 2059 2063 1:CAS:528:DC%2BD3MXnvFSi 11145492 10.1016/S0140-6736(00)03403-6 (Pubitemid 32009821)
82. S.K. Quella C.L. Loprinzi D.L. Barton, et al. 2000 Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial J Clin Oncol 18 1068 1074 1:CAS:528:DC%2BD3cXitVCgsb8%3D 10694559
83. T.D. Shanafelt D.L. Barton A.A. Adjei, et al. 2002 Pathophysiology and treatment of hot flashes Mayo Clin Proc 77 1207 1218 1:CAS:528: DC%2BD38XptVCrtL8%3D 12440557 10.4065/77.11.1207
84. Y. Jin Z. Desta V. Stearns, et al. 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D 15632378
85. K.J. Pandya G.R. Morrow J.A. Roscoe, et al. 2005 Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial Lancet 366 818 824 1:CAS:528:DC%2BD2MXpslars7c%3D 16139656 10.1016/S0140-6736(05)67215-7 (Pubitemid 41557381)
86. J. Filshie T. Bolton D. Browne, et al. 2005 Acupuncture and self acupuncture for long-term treatment of vasomotor symptoms in cancer patients: audit and treatment algorithm Acupunct Med 23 171 180 16430125 10.1136/aim.23.4.171
87. J.S. Jacobson A.B. Troxel J. Evans, et al. 2001 Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer J Clin Oncol 19 2739 2745 1:STN:280:DC%2BD3M3lsVOlsQ%3D%3D 11352967
88. E. Liske W. Hanggi H.H. Henneicke-von Zepelin, et al. 2002 Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect J Womens Health Gend Based Med 11 163 174 1:STN:280:DC%2BD383js12mtw%3D%3D 11975864 10.1089/152460902753645308 (Pubitemid 34296298)
89. R.R. Freedman S. Woodward 1992 Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring Am J Obstet Gynecol 167 436 439 1:STN:280:DyaK38zlvFWktQ%3D%3D 1497048
90. M. Ueda 2004 A 12-week structured education and exercise program improved climacteric symptoms in middle-aged women J Physiol Anthropol Appl Human Sci 23 143 148 15472458 10.2114/jpa.23.143 (Pubitemid 40357705)
91. T.J. Postma J.J. Heimans 2000 Grading of chemotherapy-induced peripheral neuropathy Ann Oncol 11 509 513 1:STN:280:DC%2BD3M%2Fms1OhsQ%3D%3D 10907941 10.1023/A:1008345613594 (Pubitemid 30431370)
92. G. Cavaletti C. Zanna 2002 Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity Eur J Cancer 38 1832 1837 1:STN:280:DC%2BD38vkslyntQ%3D%3D 12204664 10.1016/S0959-8049(02)00229-0 (Pubitemid 35247468)
93. A.J. Windebank W. Grisold 2008 Chemotherapyinduced neuropathy J Peripher Nerv Syst 13 27 46 1:CAS:528:DC%2BD1cXltl2ktrc%3D 18346229 10.1111/j.1529-8027. 2008.00156.x
94. L. Livi F. Paiar R. Santini, et al. 2006 Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer Anticancer Drugs 17 1081 1085 1:CAS:528:DC%2BD28XpvFersbc%3D 17001182 10.1097/01.cad.0000231478.22901.6e (Pubitemid 44454786)
95. V. Chaudhry E.K. Rowinsky S.E. Sartorius, et al. 1994 Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies Ann Neurol 35 304 311 1:STN:280: DyaK2c7mvVCgsA%3D%3D 7907208 10.1002/ana.410350310
96. P.A. Forsyth C. Balmaceda K. Peterson, et al. 1997 Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing J Neurooncol 35 47 53 1:STN:280:DyaK2svhtFClsA%3D%3D 9266440 10.1023/A: 1005805907311 (Pubitemid 27361845)
97. V. Chaudhry M. Chaudhry T.O. Crawford, et al. 2003 Toxic neuropathy in patients with preexisting neuropathy Neurology 60 337 340 1:STN:280: DC%2BD3s%2FktlWntw%3D%3D 12552058 10.1001/archneur.60.3.337 (Pubitemid 36314358)
98. D. Cella A. Peterman S. Hudgens, et al. 2003 Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane) Cancer 98 822 831 1:CAS:528:DC%2BD3sXntVWgurY%3D 12910528 10.1002/cncr.11578 (Pubitemid 36959280)
99. A.B. Miller B. Hoogstraten M. Staquet, et al. 1981 Reporting results of cancer treatment Cancer 47 207 214 1:STN:280:DyaL3M7htFOltw%3D%3D 7459811 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 (Pubitemid 11167383)
100. J.E. Hammack J.C. Michalak C.L. Loprinzi, et al. 2002 Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy Pain 98 195 203 1:CAS:528:DC%2BD38XkvFyrsbc%3D 12098632 10.1016/S0304-3959(02)00047-7 (Pubitemid 34722482)
101. A. Pace A. Savarese M. Picardo, et al. 2003 Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy J Clin Oncol 21 927 931 1:CAS:528:DC%2BD2cXpsVGqs7o%3D 12610195 10.1200/JCO.2003.05. 139 (Pubitemid 46606454)
102. E.M. Smets B. Garssen A.L. Schuster-Uitterhoeve, et al. 1993 Fatigue in cancer patients Br J Cancer 68 220 224 1:STN:280:DyaK3szkvFOjtg%3D%3D 8347475
103. D. Irvine L. Vincent J.E. Graydon, et al. 1994 The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals Cancer 17 367 378 1:STN:280:DyaK2M%2Fkt1artw%3D%3D
104. G.A. Curt W. Breitbart D. Cella, et al. 2000 Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition Oncologist 5 353 360 1:STN:280:DC%2BD3crgtFWnug%3D%3D 11040270 10.1634/theoncologist.5-5-353
105. T. Mallinson D. Cella J. Cashy, et al. 2006 Giving meaning to measure: linking self-reported fatigue and function to performance of everyday activities J Pain Symptom Manage 31 229 241 16563317 10.1016/j.jpainsymman.2005.07.012
106. A. Glaus 1998 Fatigue in patients with cancer Analysis and assessment. Recent Results Cancer Res 145 I XI 1:STN:280:DyaK1c3ht1yltg%3D%3D
107. M.E. Mast 1998 Correlates of fatigue in survivors of breast cancer Cancer Nurs 21 136 142 1:STN:280:DyaK1c3hslKrug%3D%3D 9556940 10.1097/00002820- 199804000-00007 (Pubitemid 28163246)
108. B. Woo S.L. Dibble B.F. Piper, et al. 1998 Differences in fatigue by treatment methods in women with breast cancer Oncol Nurs Forum 25 915 920 1:STN:280:DyaK1czgvVGkug%3D%3D 9644708
109. M.A. Andrykowski S.L. Curran R. Lightner 1998 Off-treatment fatigue in breast cancer survivors: a controlled comparison J Behav Med 21 1 18 1:STN:280:DyaK1c3gvVKgtw%3D%3D 9547419 10.1023/A:1018700303959 (Pubitemid 28146209)
110. G. Berglund C. Bolund T. Fornander, et al. 1991 Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients Eur J Cancer 27 1075 1081 1:STN:280:DyaK38%2FmvVKntw%3D%3D 1683557 10.1016/0277-5379(91)90295-O
111. D.M. Hann P.B. Jacobsen L.M. Azzarello, et al. 1998 Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory Qual Life Res 7 301 310 1:STN:280:DyaK1c3ntlWgtg%3D%3D 9610214 10.1023/A:1008842517972 (Pubitemid 28207019)
112. B.R. Ferrell M.M. Grant B.M. Funk, et al. 1998 Quality of life in breast cancer survivors: implications for developing support services Oncol Nurs Forum 25 887 895 1:STN:280:DyaK1czgvVGktw%3D%3D 9644705
113. J.A. Broeckel P.B. Jacobsen J. Horton, et al. 1998 Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer J Clin Oncol 16 1689 1696 1:STN:280:DyaK1c3ks1aqsA%3D%3D 9586880
114. F. Dimeo B.G. Rumberger J. Keul 1998 Aerobic exercise as therapy for cancer fatigue Med Sci Sports Exerc 30 475 478 1:STN:280:DyaK1c3islSntQ%3D%3D 9565925
115. M.L. McNeely K.L. Campbell B.H. Rowe, et al. 2006 Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis CMAJ 175 34 41 16818906